Australia lags behind other countries in developing a national policy framework for newborn screening
Since the late 1960s, newborn bloodspot screening (NBS) programs have successfully integrated public health and clinical medicine to identify and treat rare disease early, preventing disability and death. The management of these programs is increasingly being challenged by opportunities offered by rapidly evolving technologies, and by different perspectives on the role of screening. For NBS programs to respond effectively and consistently, a national mechanism is required to define and monitor standards and guide the introduction of new tests and technologies. This mechanism exists (or is in development) in many countries, but not in Australia.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.